

Managing Acne in Adult Women

Video References

1. Skin conditions by the numbers. American Academy of Dermatology Association.
<https://www.aad.org/media/stats-numbers>. Accessed 22 Sep 2021.
2. Skoza N, Tolino E, Mambrin A, et al. Adult acne versus adolescent acne: a retrospective study of 1,167 patients. *J Clin Aesthet Dermatol*. 2018;11(1):21–25
3. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. *J Am Acad Dermatol*. 2008;58(1):56-59.
4. Kamangar F, Shinkai K. Acne in the adult female patient: a practical approach. *Int J Dermatol*. 2012;51:1162–1174
5. Tan JKL, Yudi L, Fung K, et al. Divergence of demographic factors associated with clinical severity compared with quality of life impact in acne. *J Cutan Med Surg*. 2008;12(5)235–242.
6. Tan AU, Schlosser BJ, Paller AS. A review of the diagnosis and treatment of acne in adult women. *Int J Womens Dermatol*. 2018; 4(2):56–71.
7. Bagatin E, Proença de Freitas TH, Rivitti Machad MC. Adult female acne: a guide to clinical practice. *An Bras Dermatol*. 2019; 94(1): 62–75.
8. Zaenglein A, Thiboutot D. Expert Committee Recommendations for Acne Management. *Pediatrics*. 2006; 118(3): 1188–1199. September 2006.
9. Webster GF, Berson D, Stein Gold L, et al. Efficacy and tolerability of once, daily tazarotene 0.1 % gel versus once daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. *Cutis*. 2001;67(June):4–9.
10. Draelos ZD, Tanghetti EM Combination Leads to Efficacious Acne Results Study Group. Optimizing the use of tazarotene for the treatment of facial acne through combination therapy. *Cutis*. 2002;69(2S):20–29.
11. Leyden J, Tanghetti E, Ling M, et al. Tazarotene 0.1 % gel versus tretinoin 0.1 % microsphere in facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Poster presentation. Maui, HI: MauiDerm 2009.
12. Shalita AR, Berson DS, Thiboutot DM, et al. Tazarotene Cream in Acne Clinical Study Investigator Group. Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. *Clin Ther*. 2004; 26: 1865– 1873.

13. Epstein EL, Stein Gold L. Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. *Clin Cosmet Invest Dermatol* 2013;6:123–125.
14. Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. *J Drugs Dermatol*. 2005;4:153– 158.
15. Bausch Health US, LLC. ARAZLO® (tazarotene) 0.045% lotion Prescribing Information. <https://www.bauschhealth.com/portals/25/pdf/pi/arazlo-pi.pdf>. Accessed 10 Sep 2021.
16. Tanghetti E, Kircik L, Green L, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. *J Drugs Dermatol*. 2019;18(6):542.
17. Tanghetti EA, Werschler WP, Lain T, et al. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. *J Drugs Dermatol*. 2020;19(1):70–77.
18. Baldwin H, Green L, Kircik L, Guenin E. Efficacy and Safety of a Novel Tazarotene 0.045% Lotion in Females and Males with Moderate-to-Severe Acne. Poster presentation. Winter Clinical Dermatology Conference 2020. 17–22 Jan 2020. Kohala Coast, HI
19. Stein Gold L, Baldwin H, Cook-Bolden F, et al. Efficacy and safety of tazarotene 0.045% lotion in female patients with moderate-to-severe acne: post-hoc analysis by age. Poster presentation. Winter Clinical 2021. *J Skin Cutan Med*. 2021;5(1 Suppl):S23, <https://jofskin.org/index.php/skin/article/view/1178>.
20. Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. *J Dermatolog Treat*. 2021;32(4):391–398.
21. Bausch Health US, LLC. ARAZLO® (tazarotene) 0.045% lotion TEWL and corneometer study data and patient acceptance survey data on file. <https://www.arazlo.com/hcp/vehicle>. Accessed 10 Sep 2021.
22. Tanghetti EA, Gold M, Sadick N, et al. Improvements in acne and skin oiliness with tazarotene 0.045% lotion in acne patients with oily skin. Poster presented at Fall Clinical Dermatology Conference. 21–24 Oct 2021. Las Vegas, Nevada.

23. Draelos ZD, Tanghetti EA. A comparative clinical demonstration of the spreadability of tazarotene lotion 0.045% versus trifarotene cream 0.005%. Poster presented at Fall Clinical Dermatology Conference. 29 Oct to 1 Nov 2020. Virtual.